

Publications et communications – 2024-2025

Publications communes (CNR-HCL, IPP et CFG)

Chauvel C, **Casalegno JS**, Visseaux B, Vieillefond V, Haim-Boukozba S, Enouf V, Chanard E, Fabre M, **Rameix-Welti MA**, **Oblette A**, Giannoli JM, Paireau J, **Josset L**, **Lina B**, **Gaymard A**, Cauchemez S, Morfin F, Nunes MC, **Bal A**. Community and Hospital-Based Laboratory Surveillance for Influenza, Respiratory Syncytial Virus, and SARS-CoV-2 During the 2023-2024 Season, Lyon, France. *J Med Virol*. 2025 Sep;97(9):e70549. doi: 10.1002/jmv.70549. PMID: 40880188; PMCID: PMC12396161.

Moisan A, **Regue H**, Rahou Y, **Gaymard A**, **Oblette A**, Avon L, **Bergaud N**, Chavignac R, Le Hingrat Q, Burrel S, Jary A, Colson P, Cappy P, Deroche L, Brodard V, Pronier C, Alessandri-Gradt E, Salmona M, Chollet L, Trémeaux P, Handala L, Fourati S, **Lina B**, **Casalegno JS**; ANRS-MIE Technology Working Group; **Rameix-Welti MA**, **Josset L**, **Bal A**. Performance of whole genome sequencing for respiratory syncytial virus: insights from the first external quality assessment, France, 2024. *Clin Microbiol Infect*. 2025 Apr;31(4):647-650. doi: 10.1016/j.cmi.2024.12.018. Epub 2024 Dec 24. PMID: 39725080.

M'nemosyme N, Frumence E, **Souply L**, Heaugwane D, Traversier N, Mercier A, Daoudi J, **Casalegno JS**, **Valette M**, Moiton MP, Manaquin R, Darieux E, Sarton R, Grimal A, Thouillot F, Deparis X, **Lina B**, **Jaffar-Bandjee MC**. Shifts in Respiratory Virus Epidemiology on Reunion Island From 2017 to 2023: Impact of COVID-19 Pandemic and Non-Pharmaceutical Interventions. *Influenza Other Respir Viruses*. 2025 Mar;19(3):e70075. doi: 10.1111/irv.70075. PMID: 40040473; PMCID: PMC11880683.

Blanquart F, Vieillefond V, Visseaux B, Abou Chakra CN, Nunes MC, Jacques A, Haim-Boukobza S, **Josset L**, Wehrle V, Deleglise G, Duret T, **Rameix-Welti MA**, **Lina B**, **Enouf V**; RELAB study group; **Bal A**. Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025. *Euro Surveill*. 2025 Feb;30(7):2500074. doi: 10.2807/1560-7917.ES.2025.30.7.2500074. PMID: 39980426; PMCID: PMC11843621.

Fourati S, **Reslan A**, **Bourret J**, **Casalegno JS**, Rahou Y, Chollet L, Pillet S, Trémeaux P, Dossou NC, Gault E, Salmona M, Imbert-Marcille BM, Mirand A, Larrat S, Moisan A, Marot S, Schnuriger A, Veyrenche N, Engelmann I, Handala L, Henry A, Stephan V, Brichler S, Avettand-Fenoel V, Zemali N, Lefeuvre C, Pronier C, Deroche L, Jaffar-Bandjee MC, Mouna L, Francois C, Regueme A, Hartard C, Rogez S, Gallais F, Ly A, Rodriguez C, Dos Santos G, Simon-Lorier E, Schwartz O, Buchrieser J, Pawlotsky JM, **Lemoine F**, Audureau E, **Rameix-Welti MA**; POLYRES investigators. Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study *Lancet Infect Dis*. 2024 Oct 14:S1473-3099(24)00570-X. doi: 10.1016/S1473-3099(24)00570-X.

Brault A, Pontais I, **Enouf V**, Debeuret C, Bloch E, Paireau J, **Rameix-Welti MA**, White M, Baudemont G, **Lina B**, Parent du Châtelet I, **Casalegno JS**, Vaux S, Cauchemez S. Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study. *Lancet Child Adolesc Health*. 2024 Oct;8(10):721-729. doi: 10.1016/S2352-4642(24)00143-3. Epub 2024 Aug 26. PMID: 39208833

Planas D, Staropoli I, Michel V, **Lemoine F**, **Donati F**, Prot M, Porrot F, Guivel-Benhassine F, **Jeyarajah B**, **Brisebarre A**, **Dehan O**, **Avon L**, Bolland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer D, Péré H, **Lina B**, Trouillet-Assant S, Hocqueloux L, Prazuck T, Simon-Loriere E, Schwartz O. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. *Nat Commun.* 2024 Mar 13;15(1):2254. doi: 10.1038/s41467-024-46490-7. PMID: 38480689; PMCID: PMC10938001

HCL (Hospices Civils de Lyon)

Grippe

Gaymard A., Picard C., Vazzoler G., Massin P., Frobert E., Sabatier M., Barthelemy M., **Valette M.**, Ottmann M., **Casalegno J.-S.**, **Lina B.** & **Escuret V.** Impact of the H274Y Substitution on N1, N4, N5, and N8 Neuraminidase Enzymatic Properties and Expression in Reverse Genetic Influenza A Viruses. *Viruses*, 2024 Mar 1;16(3):388. doi: 10.3390/v16030388. PMID: 38543754; PMCID: PMC10975200.

Mommert-Tripon M., Parraud D., Grosbois C., **Gaymard A.**, Cheynet V., **Lina B.**, Oriol G., Laurent F., Dupré C., Semanas Q., **Bal A.**, Generenaz L., Pons S., Brengel-Pesce K., Guichard A., Mouton W., Morfin F., Fleurie A. & Trouillet-Assant S. Advancing respiratory virus diagnostics: integrating the nasal IFN-I score for improved viral detection. *eBioMedicine*, 2024. Dec;110:105450. doi: 10.1016/j.ebiom.2024.105450. Epub 2024 Nov 21. PMID: 39577117; PMCID: PMC11617986.

Clercq A, Blanquart F, Vieillefond V, Visseaux B, Chakra CNA, Nunes MC, Jacques A, Haim-Boukobza S, Wehrle V, Deleglise G, Duret T, Bernard-Stoecklin S, Bercoff DP, Lina B, Rameix-Welti MA, Josset L, Enouf V; RELAB study group; **Bal A.** Influenza vaccine effectiveness and genetic diversity: insights from end-of-season community surveillance, France, 2024-2025. *Emerg Microbes Infect.* 2025 Sep 15:2562045. doi: 10.1080/22221751.2025.2562045. Epub ahead of print. PMID: 40955037.

SARS-CoV-2

Sentis C., Parraud D., Billaud G., **Valette M.**, **Bouscambert-Duchamp M.**, **Lina B.**, Morfin F. & **Gaymard A.** Performance of Subgenomic RT-PCR for Predicting SARS-CoV-2 Infectivity Compared to Genomic RT-PCR and Culture Isolation. *Journal of Medical Virology*, 2025. May;97(5):e70363. doi: 10.1002/jmv.70363. PMID: 40272020; PMCID: PMC12020333.

Wallet F, Richard J.-C., Reuter J., **Gaymard A.**, Greil R., Martin-Blondel G., Andrejak C., Yazdanpanah Y., Burdet C., Diehl J.-L., Hites M., Ader F., Susen S., Mentré F. & Dupont A. sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial. *Scientific Reports*, 2025. Apr 24;15(1):14348. doi: 10.1038/s41598-025-95122-7. PMID: 40274842; PMCID: PMC1202249.

Viermyr HK, Tonby K, Ponzi E, Trouillet-Assant S, Poissy J, Arribas JR, Dyon-Tafani V, **Bouscambert-Duchamp M**, Assoumou L, Halvorsen B, Tekin NB, Diallo A, De Gastines L, Munthe LA, Murphy SL, Ueland T, Michelsen AE, Lund-Johansen F, Aukrust P, Mootien J, Dervieux B, Zerbib Y, Richard JC, Prével R, Malvy D, Timsit JF, Peiffer-Smadja N, Roux D, Piroth L, Ait-Oufella H, Vieira C, Dalgard O, Heggelund L, Müller KE, Møller JH, Kildal AB, Skogen V, Aballi S, Sjøberg Øgaard JD, Dyrhol-Riise AM, Tveita A, Alirezaylavasani A, Costagliola D, Yazdanpanah Y, Olsen IC, Dahl TB, Kared H, Holten AR, Trøseid M. Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial. *EBioMedicine*. 2025 Jan;111:105511. doi: 10.1016/j.ebiom.2024.105511. Epub 2024 Dec 27. PMID: 39731852; PMCID: PMC11743795

Beaulieu M., **Gaymard A.**, Massonnaud C., Peiffer-Smadja N., **Bouscambert-Duchamp M.**, Carcelain G., Lingas G., Mentré F., Ader F., Hites M., Poignard P. & Guedj J. Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial. *Journal of Antimicrobial Chemotherapy*, 2024. Nov 4;79(11):2887-2895. doi: 10.1093/jac/dkae301. PMID: 39236218; PMCID: PMC11531825.

Hites M., Massonnaud C. R., Jamard S., Goehringer F., Danion F., Reignier J., Castro N. de, Garot D., Lapique E. L., Lacombe K., Tolsma V., Faure E., Malvy D., Staub T., Courjon J., Cazenave-Roblot F., Riise A. M. D., Leturnier P., Martin-Blondel G., Roger C., Akinosoglou K., Moing V. L., Piroth L., Sellier P., Lescure X., Trøseid M., Clevenbergh P., Dalgard O., Gallien S., Gousseff M., Loubet P., Vardon-Bounes F., Visée C., Belkhir L., Botelho-Nevers É., Cabié A., Kotanidou A., Lanternier F., Rouveix-Nordon E., Silva S., Thiery G., Poignard P., Carcelain G., Diallo A., Mercier N., Terzic V., **Bouscambert-Duchamp M.**, **Gaymard A.**, Traubad M. A., Destras G., **Josset L.**, Belhadi D., Billard N., Guedj J., Han T.-H.-L., Couffin-Cadiergues S., Dechanet A., Delmas C., Esperou H., Fougere-Leurent C., Mestre S. L., Métois A., Noret M., Bally I., Dergan-Dylon S., Tubiana S., Kalif O., **Bergaud N.**, Leveau B., Eustace J., Greil R., Hajdu E., Halanova M., Paiva J.-A., Piekarska A., Baño J. R., Tonby K., Trojānek M., Tsiodras S., Unal S., Burdet C., Costagliola D., Yazdanpanah Y., Peiffer-Smadja N., Mentré F., Ader F. & Group D. study. Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial. *Journal of Infection*, 2024 Mar;88(3):106120. doi: 10.1016/j.jinf.2024.106120. Epub 2024 Feb 16. PMID: 38367705.

Smadja D. M., Massonnaud C. R., Philippe A., Rosa M., Luneau S., Rauch A., Peiffer-Smadja N., Gagneux-Brunon A., Poissy J., Gruet M., Ung A., Pourcher V., Raffi F., Piroth L., Bouiller K., Esperou H., Delmas C., Belhadi D., Diallo A., Saillard J., Dechanet A., Mercier N., Dupont A., Lescure F.-X., Goehringer F., Jaureguiberry S., Danion F., Tolsma V., Cabie A., Courjon J., Leroy S., Mootien J., Mourvillier B., Gallien S., Lanoix J.-P., Botelho-nevers E., Wallet F., Richard J.-C., Reuter J., **Gaymard A.**, Greil R., Martin-Blondel G., Andrejak C., Yazdanpanah Y., Burdet C., Diehl J.-L., Hites M., Ader F., Susen S., Mentré F. & Dupont A. sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial. *Scientific Reports*, 2025. Apr 24;15(1):14348. doi: 10.1038/s41598-025-95122-7. PMID: 40274842; PMCID: PMC12022249.

VRS

Chauvel C, Horvat C, Javouhey E, Gillet Y, Hassenboehler J, Chakra CNA, Ragouilliaux C, Plaisant F, Ploin D, Butin M, **Casalegno JS**, Nunes MC. Changes in Respiratory Syncytial Virus-Associated Hospitalisations Epidemiology After Nirsevimab Introduction in Lyon, France. *Influenza Other Respir Viruses*. 2024 Dec;18(12):e70054. doi: 10.1111/irv.70054. PMID: 39702765; PMCID: PMC11658964.

Howerton E, Williams TC, **Casalegno JS**, Dominguez S, Gunson R, Messacar K, Metcalf CJE, Park SW, Viboud C, Grenfell BT. Using COVID-19 pandemic perturbation to model RSV-hMPV interactions and potential implications under RSV interventions. Nat Commun. 2025 Aug 6;16(1):7261. doi: 10.1038/s41467-025-62358-w. PMID: 40770182; PMCID: PMC12328645.

Guo L, Kenmoe S, Miyake F, Chung A, Zhang H, Bandeira T, Caballero MT, **Casalegno JS**, Fasce R, Giorgi C, Heikkinen T, Huang QS, Katama EN, Keck JW, Liu E, Markic J, Moore HC, Moyes J, Rath BA, Romero C, Wang Q, Werner M, Yung CF; Respiratory Virus Global Epidemiology Network; Nair H, Li Y; PROMISE investigators. Respiratory syncytial virus hospitalisation by chronological month of age and by birth month in infants. Nat Commun. 2025 Jul 3;16(1):6109. doi: 10.1038/s41467-025-61400-1. PMID: 40610449; PMCID: PMC12229519.

Communications orales

Casalegno JS, 6^e journées du Groupement Français du Groupe Francophone de Réanimation et Urgences Pédiatriques (GFRUP), maison de la réanimation, Paris : Physiopathologie de la grippe sévère : Pourquoi est-elle parfois plus agressive ? Quid de l'atteinte multi-organes ? Septembre 2025

Casalegno JS, Congrès Preuves & Pratiques 2025, Cité internationale, Lyon : VRS, du nourrisson au patient âgé. Avril 2025

Casalegno JS, Commission de la Transparence (Haute Autorité de Santé) Expert extérieur dossier Beyfortus (réévaluation à l'initiative de la commission de la transparence) 2024

Casalegno JS, Réseau PROMISE. Présentation : Surveillance du VRS dans le cadre de l'introduction du nirsevimab en France. 2024

Casalegno JS, 44^e réunion interdisciplinaire de chimiothérapie anti-infectieuse (RICAI), Paris : Environnement urbain et épidémiologie du VRS. 2024

Casalegno JS, Fêtes de la science, Musée des Confluences, Lyon : Du sang vicié aux épidémies. 2024

Casalegno JS, session SFM, congrès BioMed, Paris, Anti-infectieux : VRS quoi de neuf en 2023. 2024

Casalegno JS, session SFM, Forum Labo, Lyon : VRS Virus, Epidémiologie, Pathologie. 2024

Escuret V, « Traitement de l'infection par les virus de la grippe » Invitation pour présentation orale au Congrès de la RICA, 16/12/2024, Paris

Gaymard A., Antiviral treatments and other innovative therapeutic strategies against influenza. AC Viroses Respiratoires de l'ANRS, Décembre 2024, Paris

Casalegno JS, CERP Workshop 2025 Dashboards for Action: Enhancing Global Surveillance of Respiratory Viruses, Lyon : BEHcl. Avril 2025

Casalegno JS, Scientific workshop on "Modelling tools for vaccination", session "Viral evolution and impacts on vaccines": vaccinales grâce à un partage en temps opportun de données cliniques et de laboratoire, Jussieu Paris : Escalating immune pressure against RSV fusion protein: Are vaccines and monoclonals on the razor's edge? Mars 2025

Bal A, Symposium Grippe et Virus respiratoires, congrès de la SFM, Lille. Évaluation de l'efficacité vaccinale en temps réel, 7 octobre 2024

IPP (Institut Pasteur Paris)

Grippe

Kissling E, Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Domegan L, Hooiveld M, Oroszi B, Martínez-Bazl, Guiomar R, Latorre-Margalef N, Mlinarić I, Lazar M, Giménez Duran J, Dürrwald R, **Enouf V**, McKenna A, deLange M, Túri G, Trobajo-Sanmartín C, Gomez V, Samuelsson Hagey T, Višekruna Vučina V, Cherciu MC, García Vazquez M, Erdwiens A, Masse S, Bennett C, Meijer A, Kristóf K, Castilla J, Rodrigues AP, Kurečić Filipović S, Ivanciuc AE, Bacci S, Kaczmarek M; Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24. European primary care VE group. *Euro Surveill.* 2025 Jun;30(23):2500011. doi: 10.2807/1560-7917.ES.2025.30.23.2500011. PMID:40511473

Bay P, Martin-Loeches I, Haudebourg AF, Lê MP, Peytavin G, **Rameix-Welti MA**, Fourati S, de Prost N. [How to manage antivirals in critically ill patients with influenza?](#) *Clin Microbiol Infect.* 2025 Jul;31(7):1157-1165. doi: 10.1016/j.cmi.2025.04.002. Epub 2025 Apr 7.

Participation à la publication – liste de publiants :

Rose AM, Lucaccioni H, Marsh K, Kirsebom F, Whitaker H, Emborg HD, Bolt Botnen A, O'Doherty MG, Pozo F, Hameed SS, Andrews N, Hamilton M, Trebbien R, Lauenborg Møller K, Marques DF, Murphy S, McQueenie R, Lopez-Bernal J, Cottrell S, Bucholtz M, Kissling E; European IVE group; Members of the European IVE group. [Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.](#) *Euro Surveill.* 2025 Feb;30(7):2500102. doi: 10.2807/1560-7917.ES.2025.30.7.2500102. PMID: 39980423 Free PMC article.

Broberg EK, Vukovikj M, Svartström O, Hasibra I, Riess M, Melidou A; Members of the ERLI-Net network. [Antigenic changes in influenza A\(H3N2\) driven by genetic evolution: Insights from virological surveillance, EU/EEA, week 40/2023 to week 9/2024.](#) *Euro Surveill.* 2024 Dec;29(50):2400395. doi: 10.2807/1560-7917.ES.2024.29.50.2400395. PMID: 39668766 Free PMC article.

Grippe zoonotique

Badra R, Zhang W, Tam JSL, Webby R, **van der Werf S**, Nikisins S, Cullinane A, Gharaibeh S, Njouom R, Peiris M, Kayali G, Heraud JM. Role and Contribution of Serological Surveillance in Animals and Exposed Humans to the Study of Zoonotic Influenza Disease Epidemiology: A Scoping Review. *Pathogens.* 2025 Jul 27;14(8):739. doi: 10.3390/pathogens14080739. PMID: 40872249; PMCID: PMC12389084.

EFSA Panel on Animal Health and Animal Welfare (AHAW); ECDC; Alvarez J, Boklund A, Dippel S, Dórea F, Figuerola J, Herskin MS, Michel V, Miranda Chueca MÁ, Nannoni E, Nielsen SS, Nonno R, Riber AB, Stegeman JA, Ståhl K, Thulke HH, Tuytens F, Winckler C, Brugerolles C, Wolff T, Parys A, Lindh E, Latorre-Margalef N, **Rameix Welti MA**, Dürrwald R, Trebbien R, **Van der Werf S**, Gisslén M, Monne I, Fusaro A, Guinat C, Bortolami A, Alexakis L, Enkirch T, Svartstrom O, Willgert K, Baldinelli F, Preite L, Grant M, Broglia A, Melidou A. Preparedness, prevention and control related to zoonotic avian influenza. **EFSA J.** 2025 Jan 29;23(1):e9191. doi: 10.2903/j.efsa.2025.9191.

Badra R, Zhang W, Tam JSL, Webby R, **van der Werf S**, Nikisins S, Cullinane A, Gharaibeh S, Njouom R, Peiris M, Kayali G, Heraud JM. Transmission Pathways of Zoonotic Influenza Viruses and Influencing Factors: A Systematic Review of Recent Findings. *Viruses*. 2025 Jun 17;17(6):857. doi: 10.3390/v17060857. PMID: 40573448; PMCID: PMC12197345.

SARS-CoV-2

Letscher H, Guilligay D, Effantin G, Amen A, Sulbaran G, Burger JA, Bossevot L, Junges L, Leonec M, Morin J, Van Tilbeurgh M, Hérate C, Gallouët AS, Relouzat F, **van der Werf S**, Cavarelli M, Dereuddre-Bosquet N, van Gils MJ, Sanders RW, Poignard P, Le Grand R, Weissenhorn W. RBD-depleted SARS-CoV-2 spike generates protective immunity in cynomolgus macaques. *NPJ Vaccines*. 2025 Mar 30;10(1):63. doi: 10.1038/s41541-025-01113-0. PMID: 40159504; PMCID: PMC11955555.

Beretta M, Martin E, Fogel O, López-Medina C, Planchais C, Bruneau T, Goncalves P, Avouac J, Berenbaum F, Sellam J, Fautrel B, Morel J, Parfait B, Di Santo JP, Behillil S, **van der Werf S**, Péré H, Latour S, Mouquet H, Miceli-Richard C. Adaptive immune responses to SARS-CoV-2 in DMARD-treated patients with chronic inflammatory rheumatisms. *RMD Open*. 2025 Jul 5;11(3):e005673. doi: 10.1136/rmdopen-2025-005673. PMID: 40617588; PMCID: PMC12228473.

Inizan C, Courtot A, Sturmach C, Griffon AF, Biron A, Bruel T, **Enouf V**, Demaneuf T, Munier S, Schwartz O, Gourinat AC, Médevielle G, Jouan M, **van der Werf S**, Madec Y, Albert-Dunais V, Dupont-Rouzeyrol M. Levels and functionality of Pacific Islanders' hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia. *PLoS Med*. 2024 Sep 26;21(9):e1004397. doi: 10.1371/journal.pmed.1004397. eCollection 2024 Sep. PMID: 39325828

Planas D, Staropoli I, Planchais C, **Yab E**, **Jeyarajah B**, **Rahou Y**, Prot M, Guivel-Benhassine F, **Lemoine F**, **Enouf V**, Simon-Lorière E*, Mouquet H*, **Rameix-Welti MA***, Schwartz O*. [Escape of SARS-CoV-2 Variants KP.1.1, LB.1, and KP3.3 From Approved Monoclonal Antibodies.](#) *Pathog Immun*. 2024 Sep 30;10(1):1-11. doi: 10.20411/pai.v10i1.752. *Contributed equally to this work

Lanièce Delaunay C, Nunes B, Monge S, de Lange M, Túri G, Machado A, Latorre-Margalef N, Mlinarić I, Lazar M, Botella Rocamora P, Erdwiens A, Sève N, Domegan L, Martínez-Baz I, Hooiveld M, Oroszi B, Guiomar R, Sperk M, Kurečić Filipović S, Pascu C, Linares Dopido JA, Dürrwald R, **Rameix-Welti MA**, McKenna A, Castilla J, van Hagen C, Knol M, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. [The potential bias introduced into COVID-19 vaccine effectiveness studies at primary care level due to the availability of SARS-CoV-2 tests in the general population.](#) *Int J Epidemiol*. 2025 Jun 11;54(4):dyaf086. doi: 10.1093/ije/dyaf086.

Laniece Delaunay C, Verdasca N, Monge S, Domegan L, Sève N, Buda S, Meijer A, Lucaccioni H, López Torrijos M, McKenna A, **Enouf V**, Dürrwald R, In't Velt E, de Valcárcel Laiglesia MÁ, Bennett C, Masse S, Erdwiens A, Hooiveld M, Mlinarić I, Túri G, Rodrigues AP, Martínez-Baz I, Lazar M, Latorre-Margalef N, Borges V, Kaczmarek M, Bacci S, Kissling E; [COVID-19 Vaccine Effectiveness Against Medically Attended Symptomatic SARS-CoV-2 Infection Among Target Groups in Europe, October 2024-January 2025, VEBIS Primary Care Network](#). European primary care VE group. *Influenza Other Respir Viruses*. 2025 May;19(5):e70120. doi: 10.1111/irv.70120. PMID: 40395132 Free PMC article.

Dugied G, Laurent EM, Attia M, Gimeno JP, Bachiri K, Samavarchi-Tehrani P, **Donati F, Rahou Y**, Munier S, Amara F, Dos Santos M, Soler N, Volant S, Pietrosemoli N, Gingras AC, Pavlopoulos GA, **van der Werf S**, Falter-Braun P, Aloy P, Jacob Y, Komarova A, Sofianatos Y, Coyaude E, Demeret C. Multimodal SARS-CoV-2 interactome sketches the virus-host spatial organization. *Commun Biol*. 2025 Mar 26;8(1):501. doi: 10.1038/s42003-025-07933-z. PMID: 40140549; PMCID: PMC11947133.

Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, O'Donnell J, Sève N, Trobajo-Sanmartín C, Buda S, Hooiveld M, Rodrigues AP, Túri G, Latorre-Margalef N, Mlinarić I, Lazar M, Maurel M, Castrillejo D, Bennett C, **Rameix-Welti MA**, Martínez-Baz I, Dürrwald R, Meijer A, Melo A, Oroszi B, Hagey TS, Kurečić Filipović S, Dijkstra F, Gomez V, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. [Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024](#). *Influenza Other Respir Viruses*. 2024 Nov;18(11):e70009. doi: 10.1111/irv.70009.

Participation à la publication – liste de publiants :

Pazukhina E, Garcia-Gallo E, Reyes LF, Kildal AB, Jassat W, Dryden M, Holter JC, Chatterjee A, Gomez K, Søråas A, Puntoni M, Latronico N, Bozza FA, Edelstein M, Gonçalves BP, Kartsonaki C, Kruglova O, Gaião S, Chow YP, Doshi Y, Duque Vallejo SI, Ibáñez-Prada ED, Fuentes YV, Hastie C, O'Hara ME, Balan V, Menkir T, Merson L, Kelly S, Citarella BW, Semple MG, Scott JT, Munblit D, Sigfrid L; ISARIC Clinical Characterisation Group and ISARIC Global Covid-19 follow up working group. [Long Covid: a global health issue - a prospective, cohort study set in four continents](#). *BMJ Glob Health*. 2024 Oct 21;9(10):e015245. doi: 10.1136/bmjgh-2024-015245. PMID: 39433402 Free PMC article.

Pazukhina E, Garcia-Gallo E, Reyes LF, Kildal AB, Jassat W, Dryden M, Holter JC, Chatterjee A, Gomez K, Søråas A, Puntoni M, Latronico N, Bozza FA, Edelstein M, Gonçalves BP, Kartsonaki C, Kruglova O, Gaião S, Chow YP, Doshi Y, Duque Vallejo SI, Ibáñez-Prada ED, Fuentes YV, Hastie C, O'Hara ME, Balan V, Menkir T, Merson L, Kelly S, Citarella BW, Semple MG, Scott JT, Munblit D, Sigfrid L; ISARIC Clinical Characterisation Group and ISARIC Global Covid-19 follow up working group. *Long Covid: a global health issue - a prospective, cohort study set in four continents*. *BMJ Glob Health*. 2024 Oct 21;9(10):e015245. doi: 10.1136/bmjgh-2024-015245. PMID: 39433402; PMCID: PMC11552006.

VRS

Eléouët JF, Galloux M, **Rameix-Welti MA**. [Visualizing Respiratory Syncytial Virus Replication in Live Mice](#). *Methods Mol Biol*. 2025 Aug;2948:281-288. doi: 10.1007/978-1-0716-4666-3_18.

J RB, V R, **Rameix-Welti MA**. [Visualization of Respiratory Syncytial Virus RNA Synthesis Sites by Ethynyl Uridine Labeling](#). *Methods Mol Biol*. 2025 Aug;2948:85-96. doi: 10.1007/978-1-0716-4666-3_6.

Marougka K, Judith D, Jaouen T, Blouquit-Laye S, Cosentino G, Berlioz-Torrent C, **Rameix-Welti MA***, Sitterlin D*. [Antagonism of BST2/Tetherin, a new restriction factor of respiratory syncytial virus, requires the viral NS1 protein](#). *PLoS Pathog*. 2024 Nov 19;20(11):e1012687. doi: 10.1371/journal.ppat.1012687. ***Contributed equally to this work**

Participation à la publication – liste de publiants :

Yamagata Y, Toizumi M, Eleouet JF, **Rameix-Welti MA**, Takeda M, Yoshida LM. [Improved RSV Neutralization Assay Using Recombinant RSV Expressing Reporter Fluorescent Protein](#). *Methods Protoc*. 2025 Jun 4;8(3):60. doi: 10.3390/mps8030060. [Improved RSV Neutralization Assay Using Recombinant RSV Expressing Reporter Fluorescent Protein](#). *Methods Protoc*. 2025 Jun 4;8(3):60. doi: 10.3390/mps8030060.

Bio-informatique

Lemoine F, Gascuel O. *The Bayesian Phylogenetic Bootstrap and its Application to Short Trees and Branches*. *Mol Biol Evol*. 2024 Nov 1;41(11):msae238. doi: 10.1093/molbev/msae238. PMID: 39514774; PMCID: PMC11600590.

Gascuel, O., & **Lemoine, F**. Measures of branch support in phylogenetics. *Models and Methods for Biological Evolution: Mathematical Models and Algorithms to Study Evolution*. Newark (NY): John Wiley & Sons, 213–234. 2024 Apr. DOI:10.1002/9781394284252.ch9

Morel, M., Zhukova, A., **Lemoine, F.**, & Gascuel, O. (2024). *Accurate detection of convergent mutations in large protein alignments with ConDor*. *Genome Biology and Evolution*, 16(4), evae040. 2024 Mar. DOI: 10.1093/gbe/evae040

Cohen-Boulakia, S., & **Lemoine, F.** (2024). *Workflows for Bioinformatics Data Integration*. *Biological Data Integration: Computer and Statistical Approaches*, 53–85. 2024 Feb. Doi : 10.1101/2023.11.20.567873

Communications orales

Présentations orales sur invitation

Da Silva K. : Conférence Jobim: Accounting for defective genomes in influenza virus consensus genome reconstruction, 2025 July 8 , Bordeaux, France

Lemoine F, « Analysis of massive bioinformatics data in the post-COVID-19 era ». 6 juin 2024, Institut DATAIA, Saclay, France.

ENOUF V. : Présentation aux grands donateurs de l'organisation de la surveillance des virus respiratoires en France

Rameix-Welti MA, Workshop de l'AC vaccin viroses respiratoires de l'ANRS MIE. Animation d'un atelier : VRS et évolution virale. 2024

Rameix-Welti MA, Réseau PROMISE. Présentation : Surveillance du VRS dans le cadre de l'introduction du nirsevimab en France. 2024

Rameix-Welti MA, Congrès Synergie et Résistances, Aix-en-Provence. Risque d'émergence de virus grippaux. 2 octobre 2024

Rameix-Welti MA, Journées Francophones de Recherche en Néonatalogie, Newcap Event Center, Paris 15e. Virologie et Épidémiologie des Bronchiolites : futures perspectives. 6 décembre 2024

Rameix-Welti MA, 44e RICAI, Palais des Congrès, Paris. POLYRES : sensibilité des VRS au Nirsevimab (Beyfortus®). 17 décembre 2024

Rameix-Welti MA, Journées de biologie clinique, Institut Imagine, Paris. Keynote : Actualités VRS. 27-28 janvier 2025

Rameix-Welti MA, XXVIII Journée de Microbiologie Clinique du Collège de Bactériologie, Virologie et Hygiène des hôpitaux, ASIEM, Paris. Super-Beyfortus® et autres vaccins à la rescousse des hospitalisations. 20 juin 2025

Lemoine F, 20e congrès national de la SFM, Symposium Grippe et Virus respiratoires. « Bioinformatique et séquençage des virus respiratoires : analyser simplement les données NGS ». 24 septembre 2025, Bordeaux.

Présentations orales sans invitation

Rameix-Welti MA, 26th Annual Conference of the European Society for Clinical Virology, Frankfurt, Allemagne. Characterization of RSV full-length viral genomes after Nirsevimab breakthrough infections in a large national observational real-world study conducted in France. 18-21 septembre 2024

Rameix-Welti MA, XIXth Negative-strand RNA Virus Meeting, Montpellier. Characterization of RSV full-length viral genomes after Nirsevimab breakthrough infections in a large national observational realworld study conducted in France. 22-27 juin 2025